Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register allows you to search for protocol and results information on:
  • interventional clinical trials that are conducted in the European Union (EU) and the European Economic Area (EEA);
  • clinical trials conducted outside the EU / EEA that are linked to European paediatric-medicine development.
  • Learn   more about the EU Clinical Trials Register   including the source of the information and the legal basis.


    The EU Clinical Trials Register currently displays   37564   clinical trials with a EudraCT protocol, of which   6160   are clinical trials conducted with subjects less than 18 years old.
    The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2015-003290-15
    Sponsor's Protocol Code Number:GTI1503
    National Competent Authority:UK - MHRA
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2016-01-13
    Trial results View results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedUK - MHRA
    A.2EudraCT number2015-003290-15
    A.3Full title of the trial
    A Multi-Centre, Open-Label, Single Arm Trial to Evaluate Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Multi-Centre, Open-Label, Single Arm Trial to Evaluate Efficacy, Pharmacokinetics, and Safety and Tolerability of IGSC 20% in Subjects with Primary Immunodeficiency
    A.3.2Name or abbreviated title of the trial where available
    GTI1503
    A.4.1Sponsor's protocol code numberGTI1503
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation PlanP/111/2016
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorGrifols Therapeutics Inc.
    B.1.3.4CountryUnited States
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportGrifols Worldwide Operations Ltd
    B.4.2CountryIreland
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationGrifols Therapeutics Inc.
    B.5.2Functional name of contact pointElsa Mondou
    B.5.3 Address:
    B.5.3.1Street Address79 TW Alexander Drive
    B.5.3.2Town/ cityResearch Triangle Park
    B.5.3.3Post codeNC 27709
    B.5.3.4CountryUnited States
    B.5.4Telephone number+19193162079
    B.5.5Fax number+19193166684
    B.5.6E-mailelsa.mondou@grifols.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameImmune Globulin Subcutaneous (Human), 20% Caprylate/Chromatography Purified (IGSC 20%)
    D.3.2Product code IGSC 20%
    D.3.4Pharmaceutical form Solution for infusion
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPSubcutaneous use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNImmune Globulin Subcutaneous (Human), 20%, Caprylate/Chromatography Purified
    D.3.9.2Current sponsor codeGRF6017
    D.3.10 Strength
    D.3.10.1Concentration unit % percent
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number20
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin No
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) Yes
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product No
    D.3.11.3.2Gene therapy medical product No
    D.3.11.3.3Tissue Engineered Product No
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) No
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product No
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product Yes
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    Primary Immunodeficiency (PI) diseases
    E.1.1.1Medical condition in easily understood language
    Primary Immunodeficiency (PI) diseases
    E.1.1.2Therapeutic area Body processes [G] - Immune system processes [G12]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10061598
    E.1.2Term Immunodeficiency
    E.1.2System Organ Class 10021428 - Immune system disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10045792
    E.1.2Term Unspecified disorder of immune mechanism
    E.1.2System Organ Class 10021428 - Immune system disorders
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level PT
    E.1.2Classification code 10064859
    E.1.2Term Primary immunodeficiency syndrome
    E.1.2System Organ Class 10010331 - Congenital, familial and genetic disorders
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    The primary objective of this Phase 3 study is to evaluate whether weekly administered IGSC 20% over a one year period will achieve less than 1 SBI per subject per year in PI subjects.
    E.2.2Secondary objectives of the trial
    • To determine if IGSC 20% replacement therapy maintains mean trough IgG levels that are comparable to the mean trough blood levels with previous IgG replacement regimen
    • To evaluate trough levels of IgG subclasses
    • To evaluate antibody levels for Streptococcus pneumoniae, Hemophilus influenzae, and Clostridium tetani
    • To evaluate the PK profile in adult PI subjects at steady state (after approximately 4 months [16 weeks]) of weekly administration of IGSC 20%
    • Trough measles antibody titers (functional assay) are an exploratory variable for informational purposes
    • To evaluate validated infections documented by positive radiograph, fever (> 38°C oral or > 39°C rectal), culture, or diagnostic testing for microorganisms e.g., bacterial, viral, fungal, or protozoal pathogens
    • To evaluate no. of days on antibiotics, no. hospitalizations and no. days work/school/activities missed due to infections
    • To assess the safety and tolerability of IGSC 20%
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    1. Adults and adolescents between the ages of 2 and 75 years (inclusive) at Screening.
    2. Documented and confirmed pre-existing diagnosis of PI with features of hypogammaglobulinemia requiring IgG replacement therapy including
    but not limited to the following: humoral-based immunodeficiency syndromes (e.g., X-linked agammaglobulinemia, common variable immunodeficiency), and combined immunodeficiency syndromes without lymphocytopenia (e.g., hyper immunoglobin [IgM] immunodeficiency syndrome). Please also refer to Exclusion Criteria.
    3. The subject has not had an SBI within the last 3 months prior to Screening and has no SBI up to the time of the Baseline Visit.
    Note: if an SBI occurs during the Screening/Previous Regimen Phase and prior to the first dose of Grifols IGSC 20%, the subject will be a
    Screen Failure
    4. Currently on IgG replacement therapy (stable regimen [dose and dosing interval] via IV or SC infusion) for ≥ 3 consecutive months.
    Subjects receiving IVIG prior to study must receive a dosage of at least 200 mg/kg per infusion.
    5. Documentation (within previous 6 months) of an IgG trough level of ≥ 500 mg/dL on current IgG replacement therapy regimen.
    6. Screening/pre-Baseline trough IgG levels must be ≥ 500 mg/dL. Note: If Screening and/or pre-Baseline trough levels (not including
    pSC#2 trough) are not above this threshold the subject will be a Screen Failure, but may be re-screened following dose adjustment of their
    original IgG replacement therapy regimen and maintaining stable dosing for a period of at least 3 consecutive months prior to Screening a second
    time.
    7. The medical records for all subjects should be available to document diagnosis, previous infections and treatment.
    8. The subject has signed an informed consent. Note: The subject must sign the informed consent form (ICF) if at least 18 years old; for children of younger age the subject's parent or legal guardian must sign the ICF and if appropriate/applicable, the subject must sign a Child Assent form approved by the Institutional Review Board or Ethics Committee (IRB/EC) per their requirements
    E.4Principal exclusion criteria
    1. Clinical evidence of any significant acute or chronic disease that, in the opinion of the PI, may interfere with successful completion of the trial or place the subject at undue medical risk
    2. The subject has had a known SAE to immunoglobulin or any severe anaphylactic reaction to blood or any blood-derived product
    3. The subject has a history of blistering skin disease, clinically significant thrombocytopenia, bleeding disorder, diffuse rash, recurrent skin infections, or other disorders where SC therapy would be contraindicated during the study
    4. The subject has isolated IgG subclass deficiency, isolated specific antibody deficiency disorder, or transient hypogammaglobulinemia of
    infancy
    5. The subject has known Selective Immunoglobulin A (IgA) Deficiency (with or without antibodies to IgA). (Note: exclusion is for the specific
    diagnostic entity. It does not exclude other forms of humoral primary immunodeficiency which have decreased IgA in addition to decreased
    IgG requiring immune globulin [IgG] replacement)
    6. Females of childbearing potential who are pregnant, have a positive pregnancy test at Screening (serum) or Baseline (urine) (human
    chorionic gonadotropin [HCG]-based assay), are breastfeeding, or unwilling to practice a highly effective method of contraception (oral,
    injectable or implanted hormonal methods of contraception, placement of an intrauterine device [IUD] or intrauterine system [IUS], condom or occlusive cap with spermicidal foam/gel/film/cream/suppository, male sterilization, or true abstinence) throughout the study
    7. The subject has significant proteinuria (dipstick proteinuria ≥ 3+, known urinary protein loss > 1 g/24 hours, or nephrotic syndrome), has
    a history of acute renal failure, has severe renal impairment (blood urea nitrogen [BUN] or creatinine more than 2.5 times the upper limit of
    normal [ULN]), and/or is on dialysis
    8. The subject has Screening Visit values of aspartate aminotransferase (AST) or alanine aminotransferase (ALT) levels exceeding 2.5 times the
    ULN for the expected normal range for the testing laboratory
    9. The subject has hemoglobin < 9 g/dL at Screening
    10. The subject has a known previous infection with or clinical signs and symptoms consistent with current hepatitis B virus (HBV) or hepatitis C
    virus (HCV) infection
    11. The subject has a history of or current diagnosis of deep venous thrombosis or thromboembolism (e.g., myocardial infarction,
    cerebrovascular accident, or transient ischemic attack); history refers to an incident in the year prior to Screening or 2 episodes over lifetime
    12. The subject is currently receiving anti-coagulation therapy which would make SC administration inadvisable (vitamin K antagonists,
    nonvitamin K antagonist oral anticoagulants
    13. The subject currently has a known hyperviscosity syndrome
    14. The subject has an acquired medical condition that is known to cause secondary immune deficiency, such as chronic lymphocytic
    leukemia, lymphoma, multiple myeloma, chronic or recurrent neutropenia (absolute neutrophil count less than 1000/µL [1.0 x
    109/L]), or HIV infection/AIDS
    15. The subject is HIV positive by NAT based on a Screening blood sample. The subject may enter the Previous Regimen Phase while the
    Screening blood sample is being tested, but will be a Screen Failure and will not undergo Baseline assessments if the HIV result is positive
    16. Subjects under 18 years of age have non-controlled arterial hypertension at a level of greater than or equal to the 90th percentile
    blood pressure (either systolic or diastolic) for their age and height or the adult subject has non-controlled arterial hypertension (systolic blood
    pressure >160 mmHg and/or diastolic blood pressure >100 mmHg)
    17. The subject is receiving any of the following medications: (a) immunosuppressants including chemotherapeutic agents, (b)
    immunomodulators, (c) long-term systemic corticosteroids defined as daily dose > 1 mg of prednisone equivalent/kg/day for > 30 days. Note:
    Intermittent courses of corticosteroids of not more than 10 days would not exclude a subject. Inhaled or topical corticosteroids are allowed
    18. The subject has known substance or prescription drug abuse
    19. The subject has participated in another clinical trial within 30 days prior to Screening (observational studies without investigative
    treatments [non-interventional] are permitted) or has received any investigational blood product, with the exception of other IgG products,
    within the previous 3 months
    20. The subject/caregiver is unwilling to comply with any aspect of the protocol, including the home SC infusions, blood sampling, and
    completion of an SC infusion diary for the duration of the study
    21. Mentally challenged subjects who cannot give independent informed consent or assent
    22. In the opinion of the PI the subject may have compliance problems with the protocol and its procedures
    E.5 End points
    E.5.1Primary end point(s)
    The primary efficacy variable is the number of SBIs. Also, the percentage of subjects with SBIs will be summarized.
    E.5.1.1Timepoint(s) of evaluation of this end point
    Sampling will be taken throughout Previous Regimen Phase and Treatment Phases 1 and 2.
    E.5.2Secondary end point(s)
    The secondary endpoint of this study is trough concentrations of total IgG of previous regimen during the Screening/Previous Regimen Phase and the IGSC 20% Treatment Stages. It is measured to determine if IGSC 20% replacement therapy maintains mean trough IgG levels that are comparable to the mean trough blood levels with the previous IgG replacement regimen.

    Additional PK parameters include average trough concentration of IgG subclasses (IgG1, IgG2, IgG3, and IgG4), and concentration of antibody levels to S. pneumoniae, H. influenzae, and C. tetani (tetanus). Trough measles antibody titers (functional assay) are an exploratory variable for informational purposes.
    For the adult (n~20) PK subset, serial samples will be collected immediately before and after SC#17 infusion at steady state. The PK profile will include total IgG concentrations at timepoints over a 7-day period. PK parameters including AUC0-7days, Cmax, and tmax will be determined by a noncompartmental model using WinNonlin.

    Other efficacy variables include rate of infection of any kind (serious and non-serious) including acute sinusitis, exacerbation of chronic sinusitis, acute otitis media, pneumonia, acute bronchitis, infectious diarrhea, etc., which will be recorded as an AE with the Investigator answering the following question affirmatively in the eCRF: “Is this an infection? (verbatim term delineating nature of infection). Validated infections documented by positive radiograph, fever (> 38°C oral or > 39°C rectal), culture, or diagnostic testing for microorganisms e.g., bacterial, viral, fungal, or protozoal pathogens (for instance, rapid streptococcal antigen test) will be analyzed separately.
    In addition, details regarding infections will include antibiotic treatment (oral, parenteral, oral plus parenteral, prophylactic, and therapeutic), and hospitalizations due to infection. Days lost from work/school/daily activities due to infections and related treatment comprise additional variables.
    E.5.2.1Timepoint(s) of evaluation of this end point
    Sampling will be taken throughout Previous Regimen Phase and Treatment Phases 1 and 2.
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy No
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled No
    E.8.1.1Randomised No
    E.8.1.2Open Yes
    E.8.1.3Single blind No
    E.8.1.4Double blind No
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo No
    E.8.2.3Other Information not present in EudraCT
    E.8.2.4Number of treatment arms in the trial1
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned5
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA31
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA No
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Czech Republic
    France
    Germany
    Hungary
    Poland
    Spain
    Sweden
    United Kingdom
    E.8.7Trial has a data monitoring committee No
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    Last Patient Last Visit
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years2
    E.8.9.1In the Member State concerned months3
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years2
    E.8.9.2In all countries concerned by the trial months3
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 Yes
    F.1.1Number of subjects for this age range: 20
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) Yes
    F.1.1.5.1Number of subjects for this age range: 10
    F.1.1.6Adolescents (12-17 years) Yes
    F.1.1.6.1Number of subjects for this age range: 20
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 20
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 10
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally Yes
    F.3.3.6.1Details of subjects incapable of giving consent
    As there are paediatric subjects, in this study assent for this group would be obtained through their parents, legal guardians or representatives.
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state15
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 60
    F.4.2.2In the whole clinical trial 60
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    The final infusion of IGSC 20% will be SC#52. One week post last SC infusion a Final Visit will occur where the patient will be assessed for the final time.
    G. Investigator Networks to be involved in the Trial
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2016-02-26
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2016-05-12
    P. End of Trial
    P.End of Trial StatusOngoing
    As of 1.2.2020, the UK is no longer an EU Member State. However, EU law still applies to the UK during the transition period
    EU Clinical Trials Register Service Desk: https://servicedesk.ema.europa.eu
    European Medicines Agency © 1995-2020 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    Legal notice
    EMA HMA